Taken together, our experiments extend the earlier body of work describing the local production of estrogen in the human skeleton, and demonstrate that aromatase inhibitors modulate this production to specifically inhibit ER+ breast cancer cell proliferation. This evidence concerns the gene CYP19A1 and breast carcinoma.